Humacyte Inc WT HUMAW

$2.15 +0.22 (11.11%)

Valuation

Market cap
—
Revenue TTM
$0
Net income TTM
$-110,780,000
PE ratio
—
Forward PE
—
Profit margin
—
Debt to equity
—

Trading

Volume
23,600
Avg volume
30,360
Day's range
$1.93 – $2.19
Shares out
—
Stochastic %K
64%
Beta
—
Analysts
Strong Sell
Price target
—

Price

Company profile

Humacyte, Inc., together with its subsidiaries, engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into pati...

Show more

Humacyte, Inc., together with its subsidiaries, engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes. Humacyte, Inc. was founded in 2004 and is headquartered in Durham, North Carolina.

Phone
919 313 9633
Website
https://www.humacyte.com
Address
2525 East North Carolina Highway 54, Durham, United States

Latest news